View Cart  

Stability at Head of FDA Good for Biotech, Says GlycoMimetics CEO

A A
Margaret Hamburg will, presumably, remain chief of the Food and Drug Administration into a second term for President Barack Obama. And that’s good for the biotech industry, said Rachel King, CEO of Gaithersburg, Md.-based GlycoMimetics and a board member of her industry’s trade group, BIO.
Washington Business Journal